おすすめの製品
由来生物
mouse
品質水準
抗体製品の状態
purified antibody
抗体製品タイプ
primary antibodies
クローン
PAb240, monoclonal
化学種の反応性
hamster, monkey, mouse, chicken, human, rat, bovine
メーカー/製品名
Chemicon®
テクニック
immunohistochemistry: suitable
immunoprecipitation (IP): suitable
western blot: suitable
アイソタイプ
IgG1
適合性
not suitable for immunohistochemistry (Paraffin)
NCBIアクセッション番号
UniProtアクセッション番号
輸送温度
wet ice
遺伝子情報
human ... TP53(7157)
詳細
p53 was discovered in 1979 as a cellular protein associating with the transforming protein of SV40 tumor virus. Since then, many different biochemical functions have been attributed to the 53 kD phosphoprotein. Experimental evidence has suggested that p53 acts as a negative regulator of cell growth in normal cells (Finlay, 1989). Thus, the inactivation or mutation of p53 may be an essential step in the development of malignancy (Lane and Benchmol, 1990). Wild-type p53 levels in normal cells and tissues were found to be very low. Mutant p53 polypeptide, however, is often found to be present at high concentrations in mammalian tumors and tumor cell lines. For example, in an immuno-histochemistry study 40% of human breast cancer showed elevated levels of mutant p53 in the cell nucleus. Mutations of the p53 protein have some characteristic features:
a) Most of them are missense point mutations giving rise to an altered protein function.
b) Many -but not all- mutant p53 proteins exhibit a common mutant structure, which can be recognized by monoclonal antibodies specific for p53 in the mutant conformation.
a) Most of them are missense point mutations giving rise to an altered protein function.
b) Many -but not all- mutant p53 proteins exhibit a common mutant structure, which can be recognized by monoclonal antibodies specific for p53 in the mutant conformation.
特異性
PAb 240 recognizes an epitope of p53 tumor suppressor protein between amino acids 211 and 220 (Gannon, 1990; Legros, 1994) in human, mouse, rat, hamster, monkey, cow and chicken. Assaying native samples (immunoprecipitation, ELISA) the PAb 240 detects only the mutant forms of p53 (Gannon, 1990; Said, 1994). In methods using denatured samples [Western blot analysis (Gannon, 1990) and immunohistochemistry of frozen tissue sections (Said, 1994; Bartek, 1991; Walker, 1991)], the PAb 240 recognizes both mutant and denatured wild-type p53.
免疫原
Epitope: aa 211-220
Murine p53-beta galactosidase fusion protein expressed in E. coli.
アプリケーション
Research Category
エピジェネティクス及び核内機能分子
エピジェネティクス及び核内機能分子
Research Sub Category
転写因子
転写因子
Detect p53 with Anti-p53 Antibody, aa 211-220, clone240 (Mouse Monoclonal Antibody), that has been shown to work in IP, WB & IHC.
Detection of p53 oncogene protein
Detection of mutant p53
Prevalence of detection using CBL 404
-50% colon carcinoma sections positive (30 samples)
-70% lung carcinoma sections positive (50 samples)
-30% carcinoma breast samples positive (50 samples)
Normal and pre-malignant tissues negative
Reacts on methacarn fixed tissue
Optimal working dilutions must be determined by the end user.
Detection of mutant p53
Prevalence of detection using CBL 404
-50% colon carcinoma sections positive (30 samples)
-70% lung carcinoma sections positive (50 samples)
-30% carcinoma breast samples positive (50 samples)
Normal and pre-malignant tissues negative
Reacts on methacarn fixed tissue
Optimal working dilutions must be determined by the end user.
関連事項
Replaces: 04-1083
物理的形状
Format: Purified
Purified mouse monoclonal in buffer containing 0.1M Tris-glycine (pH 7.4), 0.15M NaCl, with 0.05% sodium azide. We recommend that each laboratory determine an optimum working titre for use in its particular application.
保管および安定性
For use within 1 month of purchase store at +4°C, for long term storage aliquot antibody into small volumes and store at -20°C.
法的情報
CHEMICON is a registered trademark of Merck KGaA, Darmstadt, Germany
免責事項
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
適切な製品が見つかりませんか。
製品選択ツール.をお試しください
保管分類コード
12 - Non Combustible Liquids
WGK
WGK 1
引火点(°F)
Not applicable
引火点(℃)
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
Jan Code
CBL404:
試験成績書(COA)
製品のロット番号・バッチ番号を入力して、試験成績書(COA) を検索できます。ロット番号・バッチ番号は、製品ラベルに「Lot」または「Batch」に続いて記載されています。
Increased expression of mutant forms of p53 oncogene in primary lung cancer.
Lancet, 335, 675-679 (1990)
The Journal of biological chemistry, 287(4), 2907-2914 (2011-12-08)
Mutant (Mt) p53 abrogates tumor suppression functions of wild-type (WT) p53 through mutant-specific, gain-of-function effects, and patients bearing Mt p53 are chemoresistant. The dominant negative effect of p53 mutants results from their aggregation propensity which causes co-aggregation of WT p53.
The Journal of biological chemistry, 294(38), 14081-14095 (2019-08-02)
TP53 is the most frequently mutated tumor suppressor gene in many cancers, yet biochemical characterization of several of its reported mutations with probable biological significance have not been accomplished enough. Specifically, missense mutations in TP53 can contribute to tumorigenesis through
The amino-terminal transforming region of simian virus 40 large T and small t antigens functions as a J domain
Molecular and cellular biology, 17, 4761-4773 (1997)
Molecules (Basel, Switzerland), 26(23) (2021-12-11)
Multidrug resistance (MDR) has posed a significant threat to cancer treatment and has led to the emergence of a new therapeutic regime of photodynamic therapy (PDT) to curb the menace. The PDT modality employs a photosensitiser (PS), excited at a
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら(テクニカルサービス)